Similar drugsTo uncover
Dosage form: & nbsp
solution for oral, local and external use
Composition:
The preparation is a mixture of sterile filtrates of phagolysates of bacteria Proteus vulgaris, Proteus mirabilis and enteropathogenic Escherichia coli of various serogroups, the most significant in the etiology of purulent-inflammatory and enteral diseases.
Excipients: Preservative - 8-hydroxyquinoline sulfate - 0.0001 g / ml (calculated content);
or 8-hydroxyquinoline sulfate monohydrate 0.0001 g / ml (in terms of 8-hydroxyquinoline sulfate, the calculated content).
Description:
It is a transparent liquid of yellow color of varying intensity, a greenish shade is permissible. Determine visually.
Biological properties. The drug causes a specific lysis of the bacteria P. vulgaris, P. mirabilis, E. coli.
Pharmacotherapeutic group:MIBP bacteriophage
ATX: & nbsp
  • Other different drugs
  • Indications:
    Treatment and prevention of purulent-inflammatory and enteral diseases, dysbacteriosis, bacterium-induced protea and enteropathogenic E. coli as part of complex therapy:
    - Diseases of the ear, throat, nose, respiratory tract and lungs (inflammation of the sinuses of the nose, middle ear, sore throat, pharyngitis, laryngitis, tracheitis, bronchitis, pneumonia, pleurisy);
    - surgical infections (suppuration of wounds, burns, abscess, phlegmon, furuncles, carbuncles, hydroadenitis, panaritium, paraproctitis, mastitis, bursitis, osteomyelitis);
    -rogenital infections (urethritis, cystitis, pyelonephritis, colpitis, endometritis, salpingo-oophoritis);
    - enteral infections (gastroenterocolitis, cholecystitis), intestinal dysbacteriosis;
    - generalized septic diseases;
    - purulent-inflammatory diseases of newborns (omphalitis, pyoderma, conjunctivitis, gastroenterocolitis, sepsis, etc.);
    - other diseases caused by a protea and E. coli.
    An important condition for effective phage therapy is the preliminary determination of the pathogenicity of the pathogen.
    Contraindications:
    Hypersensitivity to the components of the drug.
    Pregnancy and lactation:
    The use of this medication during pregnancy and during breast-feeding is possible in the presence of infections caused by phagosensitive strains of bacteria (on the recommendation of a doctor).
    Dosing and Administration:

    The drug is used for oral administration (through the mouth), rectal administration, applications, irrigation, insertion into the wound cavity, vagina, uterus, nose, sinuses and drained cavities.

    RECOMMENDED DOSAGE OF THE PREPARATION

    AGE OF PATIENT

    DOSE FOR 1 RECEPTION (ml)

    inwards

    in the enema

    0-6 months

    5

    5-10

    6-12 months

    10

    10-20

    from 1 year to 3 years

    15

    20-30

    from 3 to 8 years

    15-20

    30-40

    from 8 years and older

    20-30

    40-50

    Treatment of purulent-inflammatory diseases with localized lesions should be carried out simultaneously both topically and by taking the drug inside within 7-20 days (according to clinical indications).

    In the event that chemical antiseptics were used before the bacteriophage was used to treat wounds, the wound should be thoroughly washed with sterile 0.9% sodium chloride solution.

    Depending on the source of infection, the bacteriophage is used:

    - In the form of irrigation, lotion and tamponization in a volume of up to 200 ml, depending on the size of the affected area. In the abscess after removal of purulent contents with puncture, the drug is administered in an amount less than the volume of the removed pus. When osteomyelitis after appropriate surgical treatment, a bacteriophage 10-20 ml is poured into the wound.

    - When injected into the cavity (pleural, articular and other limited cavities) to 100 ml, then leave capillary drainage, through which the bacteriophage is injected for several days.

    - With cystitis, pyelonephritis, urethritis, the drug is taken orally.If the cavity of the bladder or renal pelvis is drained, the bacteriophage is injected through the cystostomy or nephrostomy 1-2 times a day for 20-50 ml in the bladder and 5-7 ml in the renal pelvis.

    - With purulent-inflammatory gynecological diseases, the drug is injected into the cavity of the vagina, the uterus in a dose of 5-10 ml daily, once with colpitis - 10 ml irrigation or tamponing 2 times a day. Tampons are pawned for 2 hours.

    - With purulent-inflammatory diseases of the ear, throat, nose, the drug is administered in a dose of 2-10 ml 1-3 times a day. Bacteriophage is used to rinse, rinse, instill, inject wetted turund (leaving them for 1 hour).

    - With enteral infections, intestinal dysbiosis, the drug is taken orally 3 times a day for 1 hour before meals. A combination of a double oral administration with a single rectal administration of a single age-related dose of a bacteriophage in the form of an enema after bowel evacuation is possible.

    Use of bacteriophage in children (up to 6 months). In sepsis, enterocolitis of newborns, including premature infants, the bacteriophage is used in the form of high enemas (through the gas outlet tube or catheter) 2-3 times a day in a dose of 5-10 ml.In the absence of vomiting and regurgitation, the use of the drug through the mouth is possible. In this case, it is mixed with breast milk. Perhaps a combination of rectal (in the form of high enemas) and oral (through the mouth) application of the drug. The course of treatment is 5-15 days. With a recurring course of the disease, repeated courses of treatment are possible. In order to prevent sepsis and enterocolitis with intrauterine infection or the danger of nosocomial infection in newborns, the bacteriophage is used as an enema 2 times a day for 5-7 days.

    In the treatment of omphalitis, pyoderma, infected wounds, the drug is applied twice daily (the gauze cloth is moistened with a bacteriophage and applied to the umbilical wound or the affected area of ​​the skin).

    Precautions for use. In case of turbidity, do not use the drug!

    Due to the content of the nutrient medium in which the bacteria can develop from the environment, causing the drug to cloud, it is necessary to observe the following rules when opening the vial:

    - Wash hands thoroughly;

    - treat the cap with an alcohol-containing solution;

    - remove the cap without opening the plug;

    - Do not put a stopper on the inner surface of the table or other objects;

    - do not leave the vial open;

    - The opened vial should be stored only in the refrigerator.

    When using small doses (2-8 drops) the drug should be taken with a sterile syringe in a volume of 0.5-1 ml.

    The preparation from the opened bottle under observance of storage conditions, the above rules and absence of turbidity can be used during the whole shelf life.

    Side effects:Not installed.
    Overdose:Not installed.
    Interaction:
    The use of the drug is possible in combination with other drugs, including antibiotics.
    Effect on the ability to drive transp. cf. and fur:None.
    Form release / dosage:
    Solution for oral, local and external use.
    Packaging:
    Solution for oral, topical and topical use in vials of 20 or 100 ml. For 8 bottles of 20 ml or 1 bottle of 100 ml with instructions for use in a pack of cardboard.
    Storage conditions:
    Transportation conditions. In accordance with SP 3.3.2.1248-03 at a temperature of 2 to 8 ° C. It is allowed to transport at a temperature of 9 to 25 ° C not more than 1 month.
    Storage conditions. The preparation is stored in accordance with SP 3.3.2.1248-03 in a dry place protected from light and inaccessible to children at a temperature of 2 to 8 ° C.
    Shelf life:
    Shelf life 2 years. The drug with expired shelf life is not subject to application.
    Terms of leave from pharmacies:Without recipe
    Registration number:LS-001998
    Date of registration:27.10.2011 / 08.05.2013
    Expiration Date:Unlimited
    The owner of the registration certificate:MICROGEN FGUP Scientific and Production Association MICROGEN FGUP Scientific and Production Association Russia
    Manufacturer: & nbsp
    Information update date: & nbsp14.01.17
    Illustrated instructions
      Instructions
      Up